IP Library Granted Patent US 8,685,248
Granted Patent B2
US 8,685,248 · App. 12/709,556 · Granted Apr 1, 2014

Purification of immunoglobulins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,685,248
App. No.
12/709,556
Granted
Apr 1, 2014
Kind
B2
Abstract

The present invention relates to a separation matrix comprised of a porous support to which ligands have been immobilized, wherein said ligands comprise at least one aliphatic sulphonamide. The nitrogen of the sulphonamide may be a secondary or tertiary amine. The invention also relates to a chromatography column that contains the described separation matrix, as well as to a method of isolating immunoglobulin-like compounds by adsorption to a separation matrix that comprises aliphatic sulphonamide ligands.

Claims (14)

1. A method of isolating antibodies from a liquid, which method comprises the steps of:

(a) providing a liquid that comprises at least one antibody;

(b) contacting said liquid with a separation matrix, which comprises one or more aliphatic sulphonamide ligands, to adsorb one or more antibodies to said matrix;

(c) passing an eluent over said matrix to release one or more antibodies; and

(d) recovering at least one antibody from a fraction of the eluent.

2. The method of claim 1 , wherein the liquid provided in step (a) additionally comprises one or more other proteins.

3. The method of claim 1 , wherein the separation matrix of step (b) is provided in a chromatography column.

4. The method of claim 3 , wherein step (b) is performed at a close to neutral pH.

5. The method of claim 1 , wherein the separation matrix of step (b) comprises a porous support; and ligands including one or more sulphonamides wherein an R group of the sulphonyl is an aliphatic compound; wherein said ligands are immobilized, optionally via spacer arms, on said porous support.

6. The method of claim 1 , wherein step (c) is a gradient elution performed by adding an eluent of decreasing salt concentration to the separation matrix.

7. The method of claim 1 , wherein step (b) is performed at a pH of or above neutral and step (c) is a gradient elution performed by adding an eluent of decreasing pH.

8. The method of claim 1 , wherein the antibodies recovered in step (d) are human or humanised antibodies.

9. The method of claim 1 , wherein the antibodies recovered in step (d) are immunoglobulin G (IgG).

10. The method of claim 1 , further comprising determining the amount of isolated antibody spectrophotometrically.

Assignments (2)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2016
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 038811/0001 →